Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Israel Center for the Treatment of Psychotrauma Israel Center for the Treatment of Psychotrauma The Israel Center for the Treatment of Psychotrauma (ICTP) affiliated with Herzog Hospital in Jerusalem, Israel, is a community-based trauma center The Israel Center for the Treatment of Psychotrauma was established in 1989 to improve the level of trauma-related services in Israel and around the world. ICTP has developed a comprehensive range of clinical and community-based services. ICTP is today involved in the research and treatment of the widespread effects of trauma caused by terrorism, war and natural disaster. ICTP has been active in its present form since 1989, but draws on a